期刊文献+

抗分泌性腹泻药物的研究进展 被引量:1

Advance in Antisecretory Drugs for Diarrheal
下载PDF
导出
摘要 病理性腹泻是人和动物常见疾病症状之一,长期以来控制腹泻是医学上一个重点。基于肠病原菌及其产物诱导肠道分泌的机理,许多学者开展了相应的调控研究。肠细胞仍是直接研究和开发新药的主要焦点,随着新靶位ENS和促分泌素等发现。 Infectious diarrhoea, particularly that due to pathogenic bacteria, is a major health problem worldwide. A variety of mechanisms have been identified by which enteropathogenic bacteria and their products can induce secretory processes in the intestine now. The major focus for many years has been the enterocyte (intracellular drug targets) and consequently this has been viewed as the most rewarding site for directing research and development into novel antisecretory agents. However, in re- cent years other secretory mechanisms have been discovered which inctude a role for endogenous secretagogues and the enteric nervous system.
出处 《中国畜牧兽医》 CAS 北大核心 2013年第2期166-168,共3页 China Animal Husbandry & Veterinary Medicine
基金 农业部948重点项目猪应激相关基因功能研究及分子标记育种技术的引进(2011-G35) 河南省科技攻关项目抗腹泻药物CFTR阻断剂研究的技术平台建立与应用
关键词 腹泻 分泌 靶位 调控 diarrhoea secretory target site regulate
  • 相关文献

参考文献10

  • 1Aikawa N, Karasawa A, Ohmori K. Effect of zaldaride maleate, an antidiarrheal compound, on intracellular cyclic nucleotide-me- diated intestinal ion secretion in rats. Eur J Pharmacol, 2000,394 (2-3) :233-236.
  • 2Banks M R,Casburn-Jones A C, Farthing M J. Cholera toxin (CT), Escherichia coli heat labile (LT) and heat stable toxin (STA) have an indirect effect on distal intestinal fluid transport in the rat small intestine. Gut,2002(suppl Ⅱ ) :A69.
  • 3Banks M R, Farthing M J, Robberecht P, et al. Anti-secretory actions of a novel vasoactive intestinal polypeptide(VIP) antago- nist in human and rat small intestine. Br J Pharmacol, 2005,144 (7) :994-1001.
  • 4DiCesare D, DuPont H L, Mathewson J J, et al. A double blind, randomized, placebo-controlled study of SP303(Provir) in the symptomatic treatment of acute diarrhea among travelers to Jamaica and Mexico. Am J Gastroenterol, 2002,97(10) : 2585- 2588.
  • 5Farthing M J. Antisecretory drugs for diarrheal disease. Dig Dis,2006,24(1-2):47-58.
  • 6Ma T, Thiagarajah J R, Yang H, et al. Thiazolidinone CFTR inhibitor identified by high throughput screening blocks cholera toxinkinduced intestinal fluid secretion. J Clin lnvest, 2002,110 (1) :1651-1658.
  • 7Plotnikoff N P, Kastin A J, Coy D H,et al. Neuropharmacologi- cal actions of enkephalin after systemic administration. Life Sci, 1976,19(8) :1283-1288.
  • 8Powell D W, Field M. Pharmacological approaches so treatment of secretory diarrhea. In Field M, Fordtran J S, Sehultz S G (eds). Secretory Diarrhea. Bethesda:American Physiological So- ciety, 1980.
  • 9Theodorou V, Chovet M, Eutamene H, et al. Antidiarrhoeal properties of a novel sigma ligand (JO 2871) on toxigenic diar- rhoea in mice: Mechanisms of action. Gut, 2002,51 (4) : 522- 528.
  • 10Turvill J L, Connor P, Farthing M J. Neurokinin 1 and 2 recep tors mediate cholera toxin secretion in rat jejunum. Gastroenter- ology, 2000,119 (4) : 1037 - 1044.

同被引文献13

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部